Editorial: Serum thymidine kinase activity: An alternative to histologic markers of cellular proliferation in canine lymphoma

Journal of Veterinary Internal Medicine

Volumn 18, Issue 5, 2004, Pages 595-596

  Madewell, Bruce R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELL ENZYME; CYCLINE; DNA; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE; TUMOR MARKER;

CANCER STAGING; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DNA SYNTHESIS; DOG DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HISTOLOGY; LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; TUMOR CELL; ANIMAL; ANIMAL DISEASE; BLOOD; DOG; ENZYMOLOGY; NOTE; PATHOLOGY;

CANIS FAMILIARIS;

ANIMALS; CELL PROLIFERATION; DOG DISEASES; DOGS; LYMPHOMA, NON-HODGKIN; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 6444234281     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<595:ESTKAA>2.0.CO;2     Document Type: Review

References (8)

1. von Euler H, Einarsson R, Olsson U, et al. Serum thymidine kinase activity in dogs with malignant lymphoma. A potent marker for prognosis and monitoring the disease. J Vet Intern Med. 2004;18:697-702.
2. Hallek M, Wanders L, Strohmeyer S, et al. Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;1:1-5.
3. O'Neill KL, Buckwalter MR, Murray BK. Thymidine kinase: Diagnostic and prognostic potential. Expert Rev Mol Diagn 2001;1:428-433.
4. Hannigan BM, Barnett YA, Armstrong DB, et al. Thymidine kinases: The enzymes and their clinical usefulness. Cancer Biother 1993;8:189-197.
5. Niakamura N, Momoi Y, Watari T, et al. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. J Vet Med Sci 1997;10:957-960.
6. Micke O, Schafer U, Wormann B, et al. Circadian variation of interleukin-2 receptors, serum thymidine kinase and beta-2 microglobulin in patients with non-Hodgkin's lymphoma and normal controls. Anticancer Res 1997;17:3007-3010.
7. Bates SE. Clinical applications of serum tumor markers. Ann Int Med 1991;115:623-638.
8. He Q, Zou PA, Lui JX, Skog S, Fornander T. The clinical significance of thymidine kinase I measurement in serum of breast cancer patients using the anti-TK1 antibody. Int J Biol Markers 2000;15:139-146.